News
Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback